Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag payment-outcomes

ICER says bluebird bio’s $2.1m gene therapy is cost-effective

pharmaphorum

APRIL 14, 2022

million price tag. million if paid through an outcomes-based contract for patients with sustained transfusion independence.” US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel in June, by endorsing its proposed $2.1

FDA

Ep. 005 – Dave Chase Podcast Transcript

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.

Health and Personal Care Stores

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies

ICER says bluebird bio’s $2.1m gene therapy is cost-effective

Ep. 005 – Dave Chase Podcast Transcript

Stay Connected